Background. Parkinson disease (PD) is a costly chronic condition in terms of managing both motor and nonmotor symptoms. The burden of disease is high for individuals, caregivers, and the health system. The aim of this study is to estimate the annual cost of PD from the household, health system, and societal perspectives. Methods. A prospective cohort study of newly referred people with PD to a specialist PD clinic in Melbourne, Australia. Participants completed baseline and monthly health resource use questionnaires and Medicare data were collected over 12 months. Results. 87 patients completed the 12-month follow-up assessments. The mean annual cost per person to the health care system was $32,556 AUD. The burden to society was an addition...
Background: The outcomes of treatment and treatment cost are very much helpful to ascertain the dise...
Lökk J, Borg S, Svensson J, Persson U, Ljunggren G. Drug and treatment costs in Parkinson's disease ...
The aim of the study is to describe current values of direct costs of Parkinson’s disease in western...
Background. Parkinson disease (PD) is a costly chronic condition in terms of managing both motor and...
Background. Parkinson disease (PD) is a costly chronic condition in terms of managing both motor and...
Objective: To assess the relationship between severity and progression of illness in Parkinson's dis...
Parkinson's disease (PD) is one of the world's fastest growing neurological disorders. Much is unkno...
Background and purpose: We aimed to estimate the lifetime cost of Parkinson's disease (PD) from the ...
To estimate the magnitude in which Parkinson’s disease (PD) symptoms and health- related quality of ...
Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide. With a prog...
Background: This study was carried out to evaluate the economic burden of Parkinson’s disease (PD) a...
Objective To estimate the magnitude in which Parkinson’s disease (PD) symptoms and health- relate...
We investigated the costs of Parkinson's Disease (PD) in 486 patients based on a survey conducted in...
The purpose of this study was to estimate the cost of illness of Parkinson’s disease in the United S...
We investigated the costs of Parkinson's Disease (PD) in 486 patients based on a survey conducted in...
Background: The outcomes of treatment and treatment cost are very much helpful to ascertain the dise...
Lökk J, Borg S, Svensson J, Persson U, Ljunggren G. Drug and treatment costs in Parkinson's disease ...
The aim of the study is to describe current values of direct costs of Parkinson’s disease in western...
Background. Parkinson disease (PD) is a costly chronic condition in terms of managing both motor and...
Background. Parkinson disease (PD) is a costly chronic condition in terms of managing both motor and...
Objective: To assess the relationship between severity and progression of illness in Parkinson's dis...
Parkinson's disease (PD) is one of the world's fastest growing neurological disorders. Much is unkno...
Background and purpose: We aimed to estimate the lifetime cost of Parkinson's disease (PD) from the ...
To estimate the magnitude in which Parkinson’s disease (PD) symptoms and health- related quality of ...
Parkinson's disease (PD) is the second most common neurodegenerative disorder worldwide. With a prog...
Background: This study was carried out to evaluate the economic burden of Parkinson’s disease (PD) a...
Objective To estimate the magnitude in which Parkinson’s disease (PD) symptoms and health- relate...
We investigated the costs of Parkinson's Disease (PD) in 486 patients based on a survey conducted in...
The purpose of this study was to estimate the cost of illness of Parkinson’s disease in the United S...
We investigated the costs of Parkinson's Disease (PD) in 486 patients based on a survey conducted in...
Background: The outcomes of treatment and treatment cost are very much helpful to ascertain the dise...
Lökk J, Borg S, Svensson J, Persson U, Ljunggren G. Drug and treatment costs in Parkinson's disease ...
The aim of the study is to describe current values of direct costs of Parkinson’s disease in western...